Distinguished in Lung Cancer

Lin P. Xu

101 Longmian Avenue, 
Nanjing, CN 
Distinguished in Lung Cancer
101 Longmian Avenue, 
Nanjing, CN 
OverviewLocationsClinical Research

Overview

Lin Xu practices in Nanjing, China. Xu is rated as a Distinguished expert by MediFind in the treatment of Lung Cancer. Their top areas of expertise are Lung Adenocarcinoma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Endoscopy, and Thymectomy.

Their clinical research consists of co-authoring 395 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 200 articles and participated in 5 clinical trials in the study of Lung Cancer.

Locations

101 Longmian Avenue, Nanjing, 211166, China
Other Locations
15 West Changle Road, Xi'an, China
No. 305, Zhongshan East Road, Nanjing, 210002, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Multi-centre Real-world Non-interventional Observational Study to Evaluate Clinical Characteristics of the Chinese Patients With Lung Malignant Tumors Who Received Surgeries or Surgeries Plus Adjuvant Therapies
A Multi-centre Real-world Non-interventional Observational Study to Evaluate Clinical Characteristics of the Chinese Patients With Lung Malignant Tumors Who Received Surgeries or Surgeries Plus Adjuvant Therapies
Enrollment Status: Completed
Publish Date: May 21, 2018
Intervention Type: Procedure
A Multi-centre Real-world Non-interventional Observational Study to Compare Prognoses of the Chinese Patients With N2 Non-small Cell Lung Cancer Who Received Adjuvant Chemotherapies and Perioperative Chemotherapies After Surgeries
A Multi-centre Real-world Non-interventional Observational Study to Compare Prognoses of the Chinese Patients With N2 Non-small Cell Lung Cancer Who Received Adjuvant Chemotherapies and Perioperative Chemotherapies After Surgeries
Enrollment Status: Completed
Publish Date: May 21, 2018
Intervention Type: Procedure
A Multi-centre Real-world Non-interventional Observational Study to Compare Effectiveness and Safety of the Minimally Invasive Surgeries of Ivor-Lewis and Mckeown in Chinese Patients With IA-IIIB Esophageal Cancer
A Multi-centre Real-world Non-interventional Observational Study to Compare Effectiveness and Safety of the Minimally Invasive Surgeries of Ivor-Lewis and Mckeown in Chinese Patients With IA-IIIB Esophageal Cancer
Enrollment Status: Completed
Publish Date: May 21, 2018
Intervention Type: Procedure
A Multi-centre Real-world Non-interventional Observational Study to Explore Clinical Characteristics of Lymph Skip Metastases and Prognoses of N2 Patients With Non-small Cell Lung Cancer
A Multi-centre Real-world Non-interventional Observational Study to Explore Clinical Characteristics of Lymph Skip Metastases and Prognoses of N2 Patients With Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: May 21, 2018
Intervention Type: Procedure
A Multi-centre Real-world Non-interventional Observational Study to Evaluate Effectiveness of Sublobar Dissection in the Chinese Patients With Non-small Cell Lung Cancer
A Multi-centre Real-world Non-interventional Observational Study to Evaluate Effectiveness of Sublobar Dissection in the Chinese Patients With Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: May 21, 2018
Intervention Type: Procedure
A Multi-centre Real-world Non-interventional Observational Study to Evaluate Effectiveness and Safety of Surgeries in the Chinese Early-stage Patients With Non-small Cell Lung Cancer
A Multi-centre Real-world Non-interventional Observational Study to Evaluate Effectiveness and Safety of Surgeries in the Chinese Early-stage Patients With Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: May 21, 2018
Intervention Type: Procedure
View 5 Less Clinical Trials

395 Total Publications

Cancer Stem Cells Shift Metabolite Acetyl-Coenzyme A to Abrogate the Differentiation of CD103+ T Cells.
Cancer Stem Cells Shift Metabolite Acetyl-Coenzyme A to Abrogate the Differentiation of CD103+ T Cells.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: July 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Xu's expertise for a condition
ConditionClose
    View All 31 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile